Malik S. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults[J]. Circulation,2004,110(10): 1245-1250.
[1]
Deedwania P C. Metabolic syndrome and vascular disease: is nature or nurture leading the new epidemic of cardiovascular disease?[J]. Circulation, 2003, 109(1): 2-4.
[6]
Ginsberg H N. Insulin resistance and cardiovascular disease[J]. J Clin Invest, 2000,106(4): 453-458.
[7]
Koning L, Malik V S, Kellogg M D,et al. Sweetened beverage consumption, incident coronary heart disease, and biomarkers of risk in men[J]. Circulation, 2012,125(14): 1735-1741.
[8]
Wu Q, Zhao Z. Inhibition of PAI-1: a new anti-thrombotic approach[J]. Curr Drug Targets Cardiovasc Haematol Disord, 2002,2(1): 27-42.
[2]
Bonora E. The metabolic syndrome and cardiovascular disease [J]. Ann Med, 2006, 38(1): 64-80.
[9]
Austin M A, King M C, Vranizan K M, et al. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk[J]. Circulation,1990, 82(2): 495-506.
[3]
Aggarwal. Metabolic syndrome and coronary artery disease in indians younger than 40 years[J]. J Endocrinol Metab, 2012: 536-538.
[10]
Pirro M, Mauriège P, Tchernof A, et al. Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the quebec cardiovascular study[J]. Atherosclerosis ,2002,160(2): 377-384.
Timóteo A T, Mota Carmo M, Cruz Ferreira R. Does metabolic syndrome predict significant angiographic coronary artery disease? [J].Revista Portuguesa De Cardiologia,2012,31(12): 769-778.
[12]
Pischon T, Boeing H, Hoffmann K. General and abdominal adiposity and risk of death in europe[J]. J Vasc Surg,2008,49(3): 811-812.
[5]
Malik S. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults[J]. Circulation,2004,110(10): 1245-1250.
[6]
Ginsberg H N. Insulin resistance and cardiovascular disease[J]. J Clin Invest, 2000,106(4): 453-458.
[13]
Poirier P. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association scientific statement on obesity and heart disease from the obesity committee of the council on nutrition, physical activity, and metabolism[J]. Circulation,2006,113(6): 898-918.
[7]
Koning L, Malik V S, Kellogg M D,et al. Sweetened beverage consumption, incident coronary heart disease, and biomarkers of risk in men[J]. Circulation, 2012,125(14): 1735-1741.
[8]
Wu Q, Zhao Z. Inhibition of PAI-1: a new anti-thrombotic approach[J]. Curr Drug Targets Cardiovasc Haematol Disord, 2002,2(1): 27-42.
[14]
Hiro T, Hirayama A, Ueda Y,et al. Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angioscopy and ultrasound: the zipangu study[J]. J Cardiol,2014,2:105-107.
[9]
Austin M A, King M C, Vranizan K M, et al. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk[J]. Circulation,1990, 82(2): 495-506.
[15]
Lavie C J, Milani R V, Ventura H O. obesity and cardiovascular disease[J]. Jac, 2009,53(21): 1925-1932.
[10]
Pirro M, Mauriège P, Tchernof A, et al. Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the quebec cardiovascular study[J]. Atherosclerosis ,2002,160(2): 377-384.
[16]
Poirier P. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss [J]. Arterioscler Thromb Vasc Biol, 2006,26(5):968-976.
Cooper-DeHoff R M, Gong Y, Handberg E M, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease[J]. Jama,2010,304(1): 61-68.
[18]
Sipahi I, Tuzcu E M, Schoenhagen P, et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis[J]. J Ame Colle Card,2006,48(4): 833-838.
[12]
Pischon T, Boeing H, Hoffmann K. General and abdominal adiposity and risk of death in europe[J]. J Vasc Surg,2008,49(3): 811-812.
[19]
Slavin T P, Feng T, Schnell A, et al. Two-marker association tests yield new disease associations for coronary artery disease and hypertension[J]. Hum Genet, 2011,130(6): 725-733.
[13]
Poirier P. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association scientific statement on obesity and heart disease from the obesity committee of the council on nutrition, physical activity, and metabolism[J]. Circulation,2006,113(6): 898-918.
[20]
TICFBPG-WA. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk[J]. Nature, 2012,478(7367): 103-109.
[14]
Hiro T, Hirayama A, Ueda Y,et al. Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angioscopy and ultrasound: the zipangu study[J]. J Cardiol,2014,2:105-107.
Denardo S J, Gong Y, Nichols W W, et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy[J]. AJM, 2010,123(8): 719-726.
[15]
Lavie C J, Milani R V, Ventura H O. obesity and cardiovascular disease[J]. Jac, 2009,53(21): 1925-1932.
[16]
Poirier P. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss [J]. Arterioscler Thromb Vasc Biol, 2006,26(5):968-976.
[17]
Cooper-DeHoff R M, Gong Y, Handberg E M, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease[J]. Jama,2010,304(1): 61-68.
[23]
Koziróg M, Poliwczak A R, Duchnowicz P, et al. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome[J]. J Pineal Res,2010,50(3): 261-266.
[18]
Sipahi I, Tuzcu E M, Schoenhagen P, et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis[J]. J Ame Colle Card,2006,48(4): 833-838.
[24]
Wu Y, Huxley R, Li L,et al. Prevalence, awareness, treatment, and control of hypertension in China: data from the China National Nutrition and health survey 2002[J]. Circulation,2008,118(25): 2679-2686.
[19]
Slavin T P, Feng T, Schnell A, et al. Two-marker association tests yield new disease associations for coronary artery disease and hypertension[J]. Hum Genet, 2011,130(6): 725-733.
[25]
Ford E S, Giles W H, Dietz W H. Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey[J]. Jama, 2002,287(3): 356-359.
Denardo S J, Gong Y, Nichols W W, et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy[J]. AJM, 2010,123(8): 719-726.
[23]
Koziróg M, Poliwczak A R, Duchnowicz P, et al. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome[J]. J Pineal Res,2010,50(3): 261-266.
[24]
Wu Y, Huxley R, Li L,et al. Prevalence, awareness, treatment, and control of hypertension in China: data from the China National Nutrition and health survey 2002[J]. Circulation,2008,118(25): 2679-2686.
[25]
Ford E S, Giles W H, Dietz W H. Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey[J]. Jama, 2002,287(3): 356-359.
2014, Vol. 25 
